Sutro Biopharma, Inc.
STROAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 7, 2026 | Stifel Nicolaus | Laura Prendergast | $48.00(+99%) | $24.15 | TheFly |
| Jun 11, 2026 | Truist Financial | $50.00(+92%) | $26.09 | TheFly | |
| May 28, 2026 | Barclays | Lukas Shumway | $56.00(+89%) | $29.69 | StreetInsider |
| May 15, 2026 | Wedbush | $60.00(+56%) | $38.42 | TheFly | |
| May 15, 2026 | H.C. Wainwright | Andrew Fein | $50.00(+30%) | $38.42 | TheFly |
| May 15, 2026 | Leerink Partners | $43.00(+12%) | $38.42 | TheFly | |
| Apr 30, 2026 | Mizuho Securities | $50.00(+41%) | $35.39 | TheFly | |
| Mar 14, 2025 | Piper Sandler | $2.00(-75%) | $8.10 | TheFly | |
| Oct 11, 2024 | Bank of America Securities | Tazeen Ahmad | $12.00(-67%) | $36.05 | StreetInsider |
| Oct 11, 2024 | H.C. Wainwright | Andrew Fein | $12.00(-67%) | $36.10 | StreetInsider |
| Aug 16, 2024 | Truist Financial | Asthika Goonewardene | $15.00(-64%) | $42.10 | StreetInsider |
| May 14, 2024 | Deutsche Bank | James Shin | $10.00(-77%) | $43.40 | StreetInsider |
| May 14, 2024 | Wedbush | David Nierengarten | $8.00(-81%) | $42.30 | StreetInsider |
| Apr 3, 2024 | Oppenheimer | Jay Olson | $10.00(-80%) | $50.90 | StreetInsider |
| Apr 3, 2024 | Piper Sandler | Edward Tenthoff | $11.00(-78%) | $50.90 | StreetInsider |
| Apr 2, 2024 | Truist Financial | Asthika Goonewardene | $18.00(-65%) | $50.90 | StreetInsider |
| Jan 13, 2023 | Truist Financial | $25.00(-69%) | $81.35 | Benzinga | |
| Jan 10, 2023 | Piper Sandler | $18.00(-78%) | $82.90 | Benzinga | |
| Jun 28, 2022 | Piper Sandler | Edward Tenthoff | $16.00(-68%) | $50.50 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wedbush | maintain | Outperform | Oct 15, 2026 |
| Citizens | maintain | Market Outperform | Aug 13, 2026 |
| Wedbush | maintain | Outperform | Aug 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2026 |
| Wedbush | upgrade | Neutral →Outperform | May 15, 2026 |
| Leerink Partners | maintain | Outperform | May 15, 2026 |
| Citizens | maintain | Market Outperform | Apr 23, 2026 |
| Citizens | maintain | Market Outperform | Apr 17, 2026 |
| Deutsche Bank | maintain | Buy | Mar 25, 2026 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Mar 24, 2026 |
| Wells Fargo | upgrade | Equal Weight →Overweight | Mar 24, 2026 |
| Citizens | upgrade | Market Perform →Market Outperform | Jan 20, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Dec 22, 2025 |
| Wells Fargo | maintain | Equal Weight | Aug 12, 2025 |
| Piper Sandler | upgrade | Neutral →Overweight | Jun 16, 2025 |
| B of A Securities | maintain | Underperform | May 19, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Apr 29, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Mar 17, 2025 |
| Wedbush | downgrade | Outperform →Neutral | Mar 14, 2025 |
| B of A Securities | downgrade | Buy →Underperform | Mar 14, 2025 |
| Citizens Capital Markets | downgrade | Market Outperform →Market Perform | Mar 14, 2025 |
| JMP Securities | maintain | Market Outperform | Dec 11, 2024 |
| Wells Fargo | maintain | Equal Weight | Dec 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 18, 2024 |
| Piper Sandler | maintain | Overweight | Oct 11, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-2.33 | $-2.19 | $9.8M | $12.0M |
| May 14, 2026 | $-2.94 | $-2.32 | $14.5M | $8.9M |
| Mar 23, 2026 | $-5.29 | $-8.16 | $11.7M | $9.3M |
| Nov 6, 2025 | $-6.70 | $-3.94 | $9.7M | $10.1M |
| Aug 7, 2025 | $-1.40 | $-3.82 | $63.7M | $15.8M |
| May 8, 2025 | $-9.10 | $-6.30 | $17.4M | $11.6M |
| Mar 13, 2025 | $-8.90 | $-8.30 | $14.8M | $12.2M |
| Nov 13, 2024 | $-5.90 | $-0.95 | $8.5M | $15.3M |
News
The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.
Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
— STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a ran…
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026.
Sutro Biopharma (NASDAQ: STRO - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Profitability This table compares Sutro Biopharma and
Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.
– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Sec…